EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cemiplimab for the treatment of patients with metastati...
Continue Reading →
